Polatuzumab vedotin

Name: Polatuzumab vedotin
Brand: MedChemExpress
SKU: HY-132253
Rating: 4.5 (1 reviews)

Cat. No.: HY-132253 Purity: 99.37%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL).

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Polatuzumab vedotin 화학구조

CAS No. : 1313206-42-6

사이즈	재고	수량
1 mg	해외재고보유	Estimated Time of Arrival: December 31
5 mg	해외재고보유	Estimated Time of Arrival: December 31
10 mg	해외재고보유	Estimated Time of Arrival: December 31
25 mg	해외재고보유	Estimated Time of Arrival: December 31
50 mg	견적 받기
100 mg	견적 받기

or 대량구매 문의

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 1 publication(s) in Google Scholar

Other Forms of Polatuzumab vedotin:

Polatuzumab vedotin (solution) In-stock

1 Publications Citing Use of MCE Polatuzumab vedotin

•Anal Chem. 2026 Mar 24;98(11):8382-8393.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
순도&문서
References
고객리뷰

제품 설명

In Vivo

Polatuzumab vedotin (0.3, 1, 3, 6, 12 mg/kg; i.v.; once) shows anti-tumor in a mouse tumour xenograft model of human diffuse large B-cell lymphoma WSU-DLCL2^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID mice (human diffuse large B-cell lymphoma WSU-DLCL2)^[2]
Dosage:	0.3, 1, 3, 6, 12 mg/kg
Administration:	I.v.; once
Result:	Showed dose-dependent tumour growth inhibition.

분자량

150000 (average)

CAS No.

1313206-42-6

Appearance

Solid

Color

White to off-white

SMILES

[Polatuzumab vedotin]

선적

Shipping with dry ice.

보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Purity: 99.37%

Select Batch:

Data Sheet (257 KB) SDS (251 KB)

COA (232 KB) Others (132 KB) SEC-HPLC (149 KB)

Handling Instructions (2659 KB)

References

[1]. Liebers N, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021 Jul 13;5(13):2707-2716. [Content Brief]

[2]. Li D, et al. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin. Br J Pharmacol. 2019 Oct;176(19):3805-3818. [Content Brief]